SCHEDULE: Adage Capital Boosts Praxis Precision Medicines Stake

Adage Capital Management, L.P. and its principals have reported an 11.28% beneficial ownership stake in Praxis Precision Medicines, Inc., holding 2,374,085 shares of common stock.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 2,374,085 shares of Praxis Precision Medicines, Inc. common stock.
• This represents 11.28% of the company's outstanding common stock.
• The percentage is calculated based on 21,045,781 shares outstanding as of July 31, 2025, as reported in the company's Quarterly Report on Form 10-Q.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Adage Capital Management, L.P. is a Delaware limited partnership, while Robert Atchinson and Phillip Gross are citizens of the United States.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investment by Adage Capital Management, L.P., which can be interpreted as a vote of confidence in Praxis Precision Medicines, Inc. This increased ownership by a reputable firm is generally viewed positively by the market, suggesting potential for future growth or stability.

Positives

• Significant institutional investment by Adage Capital Management, L.P., a well-known investment adviser, signals confidence in Praxis Precision Medicines, Inc.
• The holding of 11.28% indicates a substantial, long-term interest from a major institutional investor.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from Praxis Precision Medicines, Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

Increased institutional ownership in a biotechnology company like Praxis Precision Medicines, Inc. can be viewed positively by the market, suggesting that sophisticated investors see potential in the company's pipeline or market position. Such filings are common in the biotech sector where long-term investment in promising drug development is typical.

Stakeholder Impact

• Shareholders: Increased institutional ownership may enhance market confidence and potentially stabilize the stock price, signaling a strong belief in the company's long-term prospects.

Key Dates

Keywords

Praxis Precision Medicines, Adage Capital Management, Institutional Ownership, Common Stock, Biotechnology, Pharmaceuticals, SEC Filing, Schedule 13G, Investment Management